- Home
- ZURA
ZURA
Zura Bio Limited
as 11-08-2024 4:00pm EST
Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.
| Founded: | 2022 | Country: | United States |
| Employees: | N/A | City: | LA JOLLA |
| Market Cap: | 279.3M | IPO Year: | N/A |
| Target Price: | $16.75 | AVG Volume (30 days): | 356.3K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.00 - $6.35 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Zura Bio Limited News
ZURA Breaking Stock News: Dive into ZURA Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Business Wire
10 days ago
Zura Bio to Participate in Two Upcoming Investor Conferences in November
Simply Wall St.
22 days ago
Bullish Zura Bio Insiders Loaded Up On US$1.01m Of Stock
Simply Wall St.
2 months ago
Institutions profited after Zura Bio Limited's (NASDAQ:ZURA) market cap rose US$45m last week but private equity firms profited the most
Business Wire
2 months ago
Zura Bio to Present at Three Upcoming Investor Conferences in September
Simply Wall St.
3 months ago
We're Not Very Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Rate
Business Wire
3 months ago
Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Business Wire
3 months ago
Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants
Compare ZURA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZURA Zura Bio Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.